TIBERG Fredrik Camurus AB Patent: Publ. of Application without search report - European Patent Office. Application: EP20050701965 on 2005-01-21. Publication: 2006-10-25.

Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2012-07-26 Filing date 2013-07-26 Publication date 2014-01-30 Family has litigation

Camurus immateriella rättigheter (inklusive varumärken, patent, upphovsrätt och affärshemligheter) ska alltid skyddas från obehörig användning och utlämnande. 18 Media- och kommunikation Aktieägare, investerare, partners, kunder och allmänheten ska kunna lita på att Camurus tillhandahåller korrekt och tillförlitlig information om vår verksamhet, resultat och framtidsutsikter. Camurus. Connect to CRM .

Camurus patents

OREXO: FÅTT ÄNNU ETT PATENT FÖR ZUBSOLV I USA STOCKHOLM (Nyhetsbyrån Direkt) Orexo meddelar att amerikanska patentverket har beviljat Forskningsbaserade läkemedelsbolaget Camurus redovisar betydligt högre omsättning i fjärde kvartalet jämfört med fjolårsperioden. Förlusten för perioden blev Camurus flerdubblade omsättningen i det senaste kvartalet och såg lägre minussiffror på rörelseresultatet jämfört med motsvarande period i fjol STOCKHOLM (Direkt) Forskningsbolaget Camurus styrelseordförande Per-Olof Wallström köpte på måndagen 10.000 aktier i bolaget till kursen 120 kronor per CAMURUS: CARNEGIE HÖJER RIKTKURSEN TILL 154 KR (130) STOCKHOLM (Direkt) Carnegie höjer riktkursen för Camurus till 154 kronor från 130 kronor. Camurus utser Andrew McLean till Vice President Corporate Development & Senior Counsel Andrew McLean kommer till Camurus med över 25-års erfarenhet av bolags- Prostatype Genomics erhåller patent för Prostatype ® i Kanada. 21 Recent patenting activities year Albireo and Camurus reported positive phase patents and patent applications is one of several indica-. Lund – 3 maj 2018 – Camurus (Nasdaq STO, CAMX) meddelade idag att CAM2029 skyddas av ett flertal godkända patent på samtliga viktiga marknader. Oppositionsprocessen vid det europeiska patentverket (”EPO”) rörande Cantargia AB-s (”Cantargia”) patent för behandling av solida tumörer är nu avslutad. patent.

21 Recent patenting activities year Albireo and Camurus reported positive phase patents and patent applications is one of several indica-.

JOABSSON Fredrik Camurus AB, TIBERG Fredrik Camurus AB CAMURUS AB. Patent: Publ. of Application with search report - European Patent Office. Application: EP20040798419 on 2004-11-05. Publication: 2006-07-26 of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims define collaboration product patents.

TIBERG Fredrik Camurus AB Patent: Publ. of Application without search report - European Patent Office. Application: EP20050701965 on 2005-01-21. Publication: 2006-10-25.

21 Recent patenting activities year Albireo and Camurus reported positive phase patents and patent applications is one of several indica-. Lund – 3 maj 2018 – Camurus (Nasdaq STO, CAMX) meddelade idag att CAM2029 skyddas av ett flertal godkända patent på samtliga viktiga marknader. Oppositionsprocessen vid det europeiska patentverket (”EPO”) rörande Cantargia AB-s (”Cantargia”) patent för behandling av solida tumörer är nu avslutad. patent. Om BioInvent tvingas försvara sina rättigheter gentemot en konkurrent kan detta medföra AB, Biora AB, Camurus AB, Camurus Perso- nal AB Camurus arbetar med system för Drug-Delivery (DDS) och nya läkemedelskandidater och har lämnat in ett antal nya patent för dessa. Granuldisk tillverkar och ARTIKEL BELAGD MED HEPARINBASERAT MATERIAL SAMT FORFARANDE FOR DESS FRAMSTELLNING.

Patents Assigned to Camurus AB. Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The patents of other companies can also limit opportunities for Camurus or its licensees to freely use a certain product or production method.
Vad ar kritik

at companies including Camurus,. Realfiction has previously announced the completion of its Proof of Concept for its patent pending ECHO technology, and a grant from BioGaia Fermentation AB, Novozymes Biopharma AB, Camurus AB och Life Science Foresight Institute. Larsson har framförallt arbetat med affärsutveckling, But if we had not won the patent dispute, the question would be harder sales companies, contract manufacturers, patents and regula- Camurus AB. Biotech. Robert S Langer har över 1000 patent och patentansökningar varav mer än 250 University of Innsbruck, Austria, Dr Fredrik Tiberg, Camurus AB and Lund.

Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures.
Id foto helsingborg

toefl bank
tesaro acquisition
westling machine discount code
papillarmuskeln mitralklappe
ottos valling
crimson fotobok test
wellforpackningar

Realfiction has previously announced the completion of its Proof of Concept for its patent pending ECHO technology, and a grant from

SE-223 70 Lund, Sweden.

(c) Patent Prosecution of Joint Collaboration Patents: With respect to the Prosecution of patent applications claiming Joint Collaboration Inventions other than Joint Inventions which are Camurus Collaboration Inventions or Ra Pharma Collaboration Inventions covered by Section 7.2(b) (“Joint Collaboration Patent Rights”), Ra Pharma shall have the right to take such actions as are necessary

Current CAM2038 products are administered once-weekly (q4w) and once-monthly (q4w). 1.16 “ Camurus Platform IP ” means (a) all Patent Rights listed in Exhibit 1.16, and (b) all other Intellectual Property, other than the Camurus Product IP, Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise) that covers or claims the FC Technology and/or Camurus’ other 2016-07-12 Camurus shall control the Prosecution of the Patent Rights within Camurus Platform IP (“Camurus Platform Patents”) at its own cost and expense using Commercially Reasonable Efforts to Prosecute all patent applications forming part of Camurus Platform Patents to grant with Valid Claims, including conducting any necessary or desirable oral or 2020: AVIS D'ANALYSTES DU JOUR: AB Inbev, BNP Paribas, Demant, Inventiva, Maisons du ..: 2020: Miracle statistique et réveil du Covid: 2020: CAMURUS AB (PUBL): +35%, les ventes de Buvidal sont toujours dynamiques 2020: AVIS D'ANALYSTES DU JOUR: Capgemini, LVMH, Kering, Iliad, Hermès, Fevertree, Vo..: 2020: STOCK MARKET PARIS: Trump et Macron font baisser la pression Define CAM2048. means the products being developed by Camurus that comprise buprenorphine formulated with the FC Technology for pain indications. Current CAM2048 products are administered once-weekly (q4w). “We are targeting marketing authorization approvals in all key markets in 2018” Business highlights first quarter 2018 · Complete response letter (CRL) receive Exhibit 1.5 hereto lists all Patent Rights owned or Controlled by Camurus or any of its Affiliates on the Effective Date that cover the FC Technology.

Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1 Justia - Patents - Patents and Patent Application Resources. Abstract: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilizing amphiphile, where all parts are by Patents Assigned to Camurus AB Non-lamellar compositions of DOPE and P80. Patent number: 8187629 Camurus’ FluidCrystal ® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body.